In this webinar, Bhavesh Patel and Shrinidhi Chakravarthy of CRA’s Life Sciences Consulting Practice explored how a customized approach could help rare disease (RD) companies identify and maintain RD patients unlocking the true potential of the product and optimizing performance. CRA presented an integrated approach on Market Sizing, Patient Finding, and Patient Tracking for successful RD asset commercialization, which applies at various stages from opportunity assessment and clinical development to commercialization and lifecycle management.
Paving the way for expanded GLP-1 coverage
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) – but their most recent incarnations, which consist of both next generation GLP-1s and...